HOUSE OF REPRESENTATIVES	H.B. NO.	1796
THIRTIETH LEGISLATURE, 2020		H.D. 2
STATE OF HAWAII

A BILL FOR AN ACT

RELATING TO HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. (a) There is established within the department of commerce and consumer affairs the insulin drug task force. The task force shall study whether cost-sharing limits should be placed on prescription insulin drugs.

(b) The director of commerce and consumer affairs, or the director's designee, shall serve as chair of the task force. The task force shall include the following members:

(1) The director of health, or the director's designee;

(2) The insurance commissioner, or the commissioner's designee; and

(3) The chairperson of the board of trustees of the Hawaii employer-union health benefits trust fund, or the chairperson's designee.

(c) The chair of the task force shall invite representatives from insurance companies, mutual benefit societies, and health maintenance organizations who offer health benefit plans with prescription drug coverage to be members of the task force.

(d) The members of the task force shall serve without compensation, but shall be reimbursed for necessary expenses, including travel expenses, incurred for service on the task force.

(e) The task force shall submit a report of its findings and recommendations, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2021.  

(f) The insulin drug task force shall dissolve on June 30, 2021.

SECTION 2. There is appropriated out of the general revenues of the State of Hawaii the sum of $           or so much thereof as may be necessary for fiscal year 2020-2021 for the purposes of this Act.

The sum appropriated shall be expended by the department of commerce and consumer affairs for the purposes of this Act.

SECTION 3. This Act shall take effect on July 1, 2050.

Report Title:

Insurance; DCCA; Insulin Drug Task Force; Appropriation

Description:

Establishes the insulin drug task force within the DCCA to study whether cost-sharing limits should be placed on prescription insulin drugs. Appropriates funds. Effective 7/1/2050. (HD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.